Alliance Pharma PLC (STU:DVL)

€ 0.52 0.005 (0.97%) Market Cap: 296.49 Mil Enterprise Value: 400.78 Mil PE Ratio: 0 PB Ratio: 1.12 GF Score: 75/100

Half Year 2024 Alliance Pharma PLC Earnings Call Transcript
Sep 30, 2024

€0.494 (+3.35%)

Earnings
Full Year 2023 Alliance Pharma PLC Earnings Call Transcript
Jun 19, 2024

€0.452 (+22.83%)

Earnings
Half Year 2023 Alliance Pharma PLC Earnings Call Transcript
Sep 26, 2023

€0.525 (+1.94%)

Earnings
Full Year 2022 Alliance Pharma PLC Earnings Call Transcript
Mar 21, 2023

€0.66 (-0.75%)

Earnings
Half Year 2022 Alliance Pharma PLC Earnings Call Transcript
Sep 20, 2022

€0.57 (+0.88%)

Earnings
Preliminary 2021 Alliance Pharma PLC Earnings Call Transcript
Mar 22, 2022

€1.05 (+0.96%)

Earnings
Half Year 2021 Alliance Pharma PLC Earnings Presentation - Pre-Recorded Transcript
Sep 21, 2021
Half Year 2021 Alliance Pharma PLC Earnings Call - Q&A Session Transcript
Sep 21, 2021

€1.2

Earnings
Full Year 2020 Alliance Pharma PLC Earnings Call Transcript
Mar 23, 2021

€1 (+3.63%)

Earnings
Half Year 2020 Alliance Pharma PLC Earnings Call Transcript
Sep 22, 2020

€0.79 (-1.25%)

Earnings
Alliance Pharma PLC Annual Shareholders Meeting Transcript
May 18, 2020
Full Year 2019 Alliance Pharma PLC Earnings Call Transcript
Apr 07, 2020

€0.73 (+1.39%)

Earnings
Half Year 2019 Alliance Pharma PLC Earnings Call Transcript
Sep 24, 2019

€0.83 (+2.47%)

Earnings
Full Year 2018 Alliance Pharma PLC Earnings Call Transcript
Mar 26, 2019

€0.78 (+6.85%)

Earnings

Full Year 2020 Alliance Pharma PLC Earnings Call Transcript

Mar 23, 2021 / 10:30AM GMT

Release Date Price: €1 (+3.63%)

Transcript

Peter Jonathan Butterfield

Alliance Pharma plc - CEO & Executive Director

Thank you very much, and good morning, everybody. I'm Pete Butterfield, CEO, and I'm here online with Andrew Franklin, our CFO, this morning. So firstly, I hope you're all keeping well, and thank you for attending this analyst meeting. Before we start the presentation, can I just check that you've all got copies of today's slides? And if not, you can find a copy on the Investors section of our website.

So I'm delighted to be able to share with you our 2020 results this morning, and despite the challenges thrown up by the COVID pandemic, I'm very pleased to report that the business has developed strongly. Robust underlying trading and strong pretax cash flow have been complemented by a strong underlying development of the business, including great progress with Kelo-cote, our #1 brand; the Nizoral integration now being substantially complete; and the successful completion of our second largest deal ever with the exciting acquisition of the Amberen brand at the end of the year.

Operationally, we're also able to

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.